Mesenchymal stromal cells inhibit proliferation of virus-specific CD8(+) T cells.

Abstract:

:Mesenchymal stromal cells (MSCs) possess broad immunomodulatory capacities that are currently investigated for potential clinical application in treating autoimmune disorders. Third-party MSCs suppress alloantigen-induced proliferation of peripheral blood mononuclear cells providing the rationale for clinical use in graft-versus-host disease (GvHD). We confirmed that MSCs strongly inhibited proliferation of CD8(+) T cells in a mixed lymphocyte reaction. However, MSCs also suppressed proliferation of T cells specifically recognizing cytomegalovirus (CMV) and influenza virus. Inhibition was dose dependent, but independent of the culture medium. MSCs inhibited proliferation of specific CD8(+) T cells and the release of IFN-γ by specific CD8(+) T cells for immunodominant HLA-A2- and HLA-B7- restricted antigen epitopes derived from CMV phosphoprotein 65 and influenza matrix protein. This is in contrast to a recently reported scenario where MSCs exert differential effects on alloantigen and virus-specific T cells potentially having an impact on surveillance and prophylaxis of patients treated by MSCs.

journal_name

Leukemia

journal_title

Leukemia

authors

Malcherek G,Jin N,Hückelhoven AG,Mani J,Wang L,Gern U,Diehlmann A,Wuchter P,Schmitt A,Chen B,Ho AD,Schmitt M

doi

10.1038/leu.2014.273

subject

Has Abstract

pub_date

2014-12-01 00:00:00

pages

2388-94

issue

12

eissn

0887-6924

issn

1476-5551

pii

leu2014273

journal_volume

28

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection.

    abstract::Chimeric antigen receptor (CAR)-T-cell is a safe and effective therapy of B-cell cancers but it is unknown if this is so in persons with prior hepatitis B virus (HBV) infection. We studied 70 subjects with advanced B-cell cancers receiving CAR-T-cell therapy, 12 of whom had chronic HBV-infection (HBsAg positive) and 2...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-020-0936-4

    authors: Wang Y,Liu Y,Tan X,Pan B,Ge J,Qi K,Cheng H,Cao J,Shi M,Yan Z,Qiao J,Jing G,Wang X,Sang W,Xia R,Zhang X,Li Z,Gale RP,Zheng J,Zhu F,Xu K

    更新日期:2020-10-01 00:00:00

  • Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines.

    abstract::Activation of the MEK/ERK/MAP kinase signaling pathway promotes the proliferation and survival of hematopoietic cells. The kinases MEK-1, MEK-2, ERK-1/MAPK and ERK-2/MAPK are activated by phosphorylation at specific sites, and these events can be monitored using phospho-specific antibodies. In this report we examined ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402400

    authors: Miranda MB,McGuire TF,Johnson DE

    更新日期:2002-04-01 00:00:00

  • Hunting for clinical translation with innate-like immune cells and their receptors.

    abstract::Allogeneic stem cell transplantation (allo-SCT) has so far been the most effective immunotherapy for hematological malignancies. However, it is becoming increasingly clear that the immunotherapeutic concepts underlying allo-SCT as well as the traditional dissection of the immune system into innate and adaptive arms ne...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2013.378

    authors: Scheper W,Gründer C,Straetemans T,Sebestyen Z,Kuball J

    更新日期:2014-06-01 00:00:00

  • Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib.

    abstract::Drug resistance is a growing area of concern. It has been shown that a small, residual pool of leukemic CD34+ progenitor cells can survive in the marrow microenvironment of chronic myeloid leukemia (CML) patients after years of kinase inhibitor treatment. Bone marrow (BM) stroma has been implicated in the long-term su...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.360

    authors: Weisberg E,Azab AK,Manley PW,Kung AL,Christie AL,Bronson R,Ghobrial IM,Griffin JD

    更新日期:2012-05-01 00:00:00

  • Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge.

    abstract::Burkitt lymphoma (BL) has a characteristic clinical presentation, morphology, immunophenotype and primary chromosomal aberration, that is, the translocation t(8;14)(q24;q32) or its variants. However, diagnostic dilemmas may arise in daily practice due to overlap of BL with subsets of other aggressive, mature B-cell ly...

    journal_title:Leukemia

    pub_type: 历史文章,杂志文章,评审

    doi:10.1038/leu.2008.281

    authors: Boerma EG,Siebert R,Kluin PM,Baudis M

    更新日期:2009-02-01 00:00:00

  • A robust xenotransplantation model for acute myeloid leukemia.

    abstract::Xenotransplantation of human acute myeloid leukemia (AML) in immunocompromised animals has been critical for defining leukemic stem cells. However, existing immunodeficient strains of mice have short life spans and low levels of AML cell engraftment, hindering long-term evaluation of primary human AML biology. A recen...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2009.143

    authors: Sanchez PV,Perry RL,Sarry JE,Perl AE,Murphy K,Swider CR,Bagg A,Choi JK,Biegel JA,Danet-Desnoyers G,Carroll M

    更新日期:2009-11-01 00:00:00

  • Cell death beyond apoptosis.

    abstract::Though the term apoptosis was originated in pathology and developmental biology as an alternative to necrosis, the tissue necrosis with inflammation is irrelevant to cell culture conditions where apoptosis is mostly studied. Furthermore, no one single morphological feature is either necessary or sufficient to define a...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2401864

    authors: Blagosklonny MV

    更新日期:2000-08-01 00:00:00

  • Linkage of proliferative and maturational abnormalities in chronic myelogenous leukemia and relevance to treatment.

    abstract::Despite recent advances in our understanding of the molecular and biological abnormalities in chronic myelogenous leukemia (CML) this new knowledge has not yet led to significant improvements in treatment. We have reviewed what is known and still unknown about the molecular and biological abnormalities in CML that may...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Clarkson B,Strife A

    更新日期:1993-11-01 00:00:00

  • A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.

    abstract::Chronic myelomonocytic leukemia (CMML) is a complex clonal hematological disorder classified among myelodysplastic (MDS)/myeloproliferative neoplasms. Prognosis is poor and there is a lack of effective treatments. The hypomethylating agent decitabine has shown activity against MDS and elderly acute myeloid leukemia, b...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/leu.2017.186

    authors: Santini V,Allione B,Zini G,Gioia D,Lunghi M,Poloni A,Cilloni D,Sanna A,Masiera E,Ceccarelli M,Abdel-Wahab O,Terenzi A,Angelucci E,Finelli C,Onida F,Pelizzari A,Ferrero D,Saglio G,Figueroa M,Levis A

    更新日期:2018-02-01 00:00:00

  • Karyotypic patterns in chronic myeloproliferative disorders: report on 74 cases and review of the literature.

    abstract::During the 15 year period 1975-1989, 74 cases of chronic myeloproliferative disorder (CMPD) were cytogenetically analyzed in our department. Thirty patients had polycythemia vera (PV), 23 had idiopathic myelofibrosis (MFS), 15 had idiopathic thrombocythemia (IT), and six had unclassifiable CMPD (UCMPD). The overall fr...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Mertens F,Johansson B,Heim S,Kristoffersson U,Mitelman F

    更新日期:1991-03-01 00:00:00

  • P190-type bcr/abl expressed in myeloid colonies in a patient with Ph1-positive acute lymphoblastic leukemia.

    abstract::In Philadelphia chromosome (Ph1)-positive acute lymphoblastic leukemia (ALL), some cytogenetic studies have suggested clonal derivation from a multipotential stem cell. The role of the product of the chimeric gene, P190, is not, however, well understood. We examined the expression of P190-type bcr/abl in single hemato...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Sadamura S,Umemura T,Hirata J,Takahira H,Yufu Y,Abe Y,Nishimura J,Nawata H

    更新日期:1992-08-01 00:00:00

  • cDNA sequencing confirms HTLV-I expression in adult T-cell leukemia/lymphoma and different sequence variations in vivo and in vitro.

    abstract::Human T-lymphotropic virus type I (HTLV-I) is the etiological agent of adult T-cell leukemia/lymphoma (ATL) and of tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM). In both diseases, expression of viral message can generally only be demonstrated by the reverse transcriptase-polymerase chain reaction...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Berneman ZN,Gartenhaus RB,Reitz MS Jr,Klotman ME,Gallo RC

    更新日期:1992-01-01 00:00:00

  • High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: a phase III study by JALSG.

    abstract::High-dose methotrexate (Hd-MTX) therapy has recently been applied to the treatment of adult acute lymphoblastic leukemia (ALL) based on pediatric protocols; however, its effectiveness for adult ALL has not yet been confirmed in a rigorous manner. We herein conducted a randomized phase III trial comparing Hd-MTX therap...

    journal_title:Leukemia

    pub_type: 杂志文章,随机对照试验

    doi:10.1038/leu.2017.283

    authors: Sakura T,Hayakawa F,Sugiura I,Murayama T,Imai K,Usui N,Fujisawa S,Yamauchi T,Yujiri T,Kakihana K,Ito Y,Kanamori H,Ueda Y,Miyata Y,Kurokawa M,Asou N,Ohnishi K,Ohtake S,Kobayashi Y,Matsuo K,Kiyoi H,Miyazaki Y,Na

    更新日期:2018-03-01 00:00:00

  • Ionising radiation and leukaemia potential risks: review based on the workshop held during the 10th Symposium on Molecular Biology of Hematopoiesis and Treatment of Leukemia and Lymphomas at Hamburg, Germany on 5 July 1997.

    abstract::Unexplained clusters of childhood leukaemia have generated concern that they may be causally related to environmental exposure to ionising radiation. The workshop provides in-depth examination of the aetiology of childhood leukaemia, patterns of clustering exhibited by cases and the influence of exposure to ionising r...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2401120

    authors: Alexander FE,Greaves MF

    更新日期:1998-08-01 00:00:00

  • Activation of Harvey ras oncogene by mutation at codon 12 is very rare in hemopoietic malignancies.

    abstract::Point mutations within codon 12 of the Harvey (H-) ras proto-oncogene have recently been implicated in the progression of hemopoietic malignancy, particularly chronic myeloid leukemia. We have analyzed DNA from 170 cases of acute and chronic leukemia by using a restriction fragment length polymorphism. No evidence for...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Browett PJ,Yaxley JC,Norton JD

    更新日期:1989-01-01 00:00:00

  • Reverse transcription polymerase chain reaction is a reliable assay for detecting leukemic colonies generated by chronic myelogenous leukemia cells.

    abstract::Single-colony karyotyping (SCK) and reverse-transcription polymerase chain reaction (RT-PCR) are two increasingly used techniques for the quantification of leukemic colonies generated by chronic myelogenous leukemia (CML) cell fractions purged or selected in vitro. Recently, the existence of Philadelphia (Ph) chromoso...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400942

    authors: Savoldo B,Sammarelli G,Dotti G,Garau D,Regazzi E,Cilloni D,Tabilio A,Rizzoli V,Carlo-Stella C

    更新日期:1998-03-01 00:00:00

  • MEIS 1 expression is downregulated through promoter hypermethylation in AML1-ETO acute myeloid leukemias.

    abstract::Retroviral insertional mutagenesis in BXH2 mice commonly induces myeloid leukemias. One of the most frequently involved genes in experimental studies is Meis 1. In contrast to other genes in murine models, Meis 1 has not been affected by recurrent chromosomal translocations or point mutations in human leukemias. We fo...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403377

    authors: Lasa A,Carnicer MJ,Aventín A,Estivill C,Brunet S,Sierra J,Nomdedéu JF

    更新日期:2004-07-01 00:00:00

  • A single course of remission reinduction chemotherapy for acute myelogenous leukemia relapsing after allogeneic bone marrow transplantation is complicated by graft-versus-host disease and followed by sustained complete remission.

    abstract::Graft-versus-host disease (GVHD) remains a major immunological complication after allogeneic bone marrow transplantation (allo-BMT), but also favors development of the beneficial graft-versus-leukemia (GVL) effect. A patient with AML-M4 (inv (16)) is described, who was given non-myeloablative remission reinduction the...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400810

    authors: Vandenberghe P,Verhoef GE,Emonds MP,Demuynck H,Zachée P,De Wolf-Peeters C,Decorte R,Cassiman JJ,Boogaerts MA

    更新日期:1997-10-01 00:00:00

  • Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.

    abstract::Renal impairment is associated with poor prognosis in multiple myeloma (MM). This subgroup analysis of the phase 3 Assessment of Proteasome Inhibition for Extending Remissions (APEX) study of bortezomib vs high-dose dexamethasone assessed efficacy and safety in patients with relapsed MM with varying degrees of renal i...

    journal_title:Leukemia

    pub_type: 杂志文章,随机对照试验

    doi:10.1038/sj.leu.2405087

    authors: San-Miguel JF,Richardson PG,Sonneveld P,Schuster MW,Irwin D,Stadtmauer EA,Facon T,Harousseau JL,Ben-Yehuda D,Lonial S,Goldschmidt H,Reece D,Bladé J,Boccadoro M,Cavenagh JD,Neuwirth R,Boral AL,Esseltine DL,Anderson KC

    更新日期:2008-04-01 00:00:00

  • Spliceosome and other novel mutations in chronic lymphocytic leukemia and myeloid malignancies.

    abstract::Spliceosome mutations represent a new generation of acquired genetic alterations that affect both myeloid and lymphoid malignancies. A substantial proportion of patients with myelodysplastic syndromes (MDSs) or chronic lymphocytic leukemia (CLL) harbor such mutations, which are often missense in type. Genotype-phenoty...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2012.86

    authors: Damm F,Nguyen-Khac F,Fontenay M,Bernard OA

    更新日期:2012-09-01 00:00:00

  • Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR-ABL1-positive acute lymphoblastic leukemia patients.

    abstract::The main reason for the unfavorable clinical outcome of BCR-ABL1-positive acute lymphoblastic leukemia (ALL) is genetic instability. However, how normal B-cell precursors acquire the genetic changes that lead to transformation has not yet been completely defined. We investigated the expression of the activation-induce...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2009.197

    authors: Iacobucci I,Lonetti A,Messa F,Ferrari A,Cilloni D,Soverini S,Paoloni F,Arruga F,Ottaviani E,Chiaretti S,Messina M,Vignetti M,Papayannidis C,Vitale A,Pane F,Piccaluga PP,Paolini S,Berton G,Baruzzi A,Saglio G,Baccar

    更新日期:2010-01-01 00:00:00

  • YAC clone H10 discriminates between 3q26.2 and 3q27 chromosome rearrangements in hematological disorders.

    abstract::To discriminate with molecular-cytogenetic resolution between 3q26.2 breakpoint, associated to various myeloproliferative disorders, and 3q27 breakpoint, recurrent in several types of non-Hodgkin lymphoma, we tested the feasibility of using a yeast artificial chromosome, YAC clone H10, mapped on 3q26.3. Fluorescent in...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Temperani P,Gandini G,Volinia S,Giacobbi F,Vaccari P,Waterfield MD,Emilia G

    更新日期:1996-02-01 00:00:00

  • Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure.

    abstract::We evaluated the impact of salvage regimens and allogeneic hematopoietic cell transplantation (allo-HCT) in acute myeloid leukemia (AML) with induction failure. Between 1993 and 2009, 3324 patients with newly diagnosed AML were enrolled in 5 prospective treatment trials of the German-Austrian AML Study Group. After fi...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2017.23

    authors: Wattad M,Weber D,Döhner K,Krauter J,Gaidzik VI,Paschka P,Heuser M,Thol F,Kindler T,Lübbert M,Salih HR,Kündgen A,Horst HA,Brossart P,Götze K,Nachbaur D,Köhne CH,Ringhoffer M,Wulf G,Held G,Salwender H,Benner A,G

    更新日期:2017-06-01 00:00:00

  • Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.

    abstract::Major molecular remission (MMR) is an important therapy goal in chronic myeloid leukemia (CML). So far, MMR is not a failure criterion according to ELN management recommendation leading to uncertainties when to change therapy in CML patients not reaching MMR after 12 months. At monthly landmarks, for different molecul...

    journal_title:Leukemia

    pub_type: 杂志文章,随机对照试验

    doi:10.1038/s41375-018-0055-7

    authors: Saussele S,Hehlmann R,Fabarius A,Jeromin S,Proetel U,Rinaldetti S,Kohlbrenner K,Einsele H,Falge C,Kanz L,Neubauer A,Kneba M,Stegelmann F,Pfreundschuh M,Waller CF,Oppliger Leibundgut E,Heim D,Krause SW,Hofmann WK,Has

    更新日期:2018-05-01 00:00:00

  • PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia.

    abstract::Chronic lymphocytic leukemia (CLL) cells with aggressive clinical properties express lipoprotein lipase (LPL), which generates activating ligands for the nuclear receptor peroxisome proliferator activated receptor (PPAR)α and allows fatty acids to be used as fuel. However, the role of PPARα in CLL is unclear. PPARα wa...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2012.329

    authors: Spaner DE,Lee E,Shi Y,Wen F,Li Y,Tung S,McCaw L,Wong K,Gary-Gouy H,Dalloul A,Ceddia R,Gorzcynski R

    更新日期:2013-04-01 00:00:00

  • Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H.

    abstract::Chronic lymphocytic leukemia (CLL) cells could be undetectable by flow cytometry or polymerase chain reaction after sequential treatment with fludarabine and Campath-1H. Concern has been raised regarding the ability to mobilize sufficient peripheral blood progenitor cells (PBPCs) for autografting after purine analogue...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403190

    authors: Montillo M,Tedeschi A,Rossi V,Cairoli R,Pungolino E,Intropido L,Cafro AM,D'Avanzo G,Farioli R,Brando B,Scarpati B,Veronese S,Morra E

    更新日期:2004-01-01 00:00:00

  • IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells.

    abstract::Tumor cells in chronic lymphocytic leukemia (CLL) are more prone to apoptosis when cultured ex vivo, because they lack prosurvival signals furnished in vivo via B-cell receptor (BCR)-dependent and -independent pathways. This study compared the susceptibility of unmutated (UM) and mutated (M) CLL B cells to spontaneous...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.12

    authors: Coscia M,Pantaleoni F,Riganti C,Vitale C,Rigoni M,Peola S,Castella B,Foglietta M,Griggio V,Drandi D,Ladetto M,Bosia A,Boccadoro M,Massaia M

    更新日期:2011-05-01 00:00:00

  • Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment.

    abstract::Tyrosine kinase inhibitors represent today's treatment of choice in chronic myeloid leukemia (CML). Allogeneic hematopoietic stem cell transplantation (HSCT) is regarded as salvage therapy. This prospective randomized CML-study IIIA recruited 669 patients with newly diagnosed CML between July 1997 and January 2004 fro...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1038/leu.2015.281

    authors: Gratwohl A,Pfirrmann M,Zander A,Kröger N,Beelen D,Novotny J,Nerl C,Scheid C,Spiekermann K,Mayer J,Sayer HG,Falge C,Bunjes D,Döhner H,Ganser A,Schmidt-Wolf I,Schwerdtfeger R,Baurmann H,Kuse R,Schmitz N,Wehmeier A,

    更新日期:2016-03-01 00:00:00

  • Restrictions in the T-cell repertoire of chronic lymphocytic leukemia: high-throughput immunoprofiling supports selection by shared antigenic elements.

    abstract::Immunoglobulin (IG) gene repertoire restrictions strongly support antigen selection in the pathogenesis of chronic lymphocytic leukemia (CLL). Given the emerging multifarious interactions between CLL and bystander T cells, we sought to determine whether antigen(s) are also selecting T cells in CLL. We performed a larg...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.362

    authors: Vardi A,Vlachonikola E,Karypidou M,Stalika E,Bikos V,Gemenetzi K,Maramis C,Siorenta A,Anagnostopoulos A,Pospisilova S,Maglaveras N,Chouvarda I,Stamatopoulos K,Hadzidimitriou A

    更新日期:2017-07-01 00:00:00

  • Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside.

    abstract::The long-term results in 130 patients with newly diagnosed acute myelogenous leukemia treated with continuous infusion high-dose ara-C (1.5 gm/m2/day x 4 days, CIHDAC) were compared with those in 264 patients treated in previous studies with standard dose ara-C (70-90 mg/m2/d x 7 days) plus either adriamycin (Ad-OAP),...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:

    authors: Ghaddar HM,Plunkett W,Kantarjian HM,Pierce S,Freireich EJ,Keating MJ,Estey EH

    更新日期:1994-08-01 00:00:00